Have Fun at Play2Cures Casual Games Fundraising Site

Taylor Carol, was a typical 11-year-old boy. When he got hit by a pitch during a baseball game in March 2006, his world turned upside down. Follow-up testing revealed something more ominous than an injured elbow - the blood cancer leukemia.



During the long grueling months that Taylor was fighting for his life, his father, software designer Jim Carol focused his energy on finding a way to help Taylor and other children going through a similar ordeal. The result: Pledgeplay (www.pledgeplay.com), an innovative, customizable online casual games and fundraising platform. The Leukemia & Lymphoma Society (LLS) launched Play2Cures (lls.play2cures.org), which employs the Plegeplay platform and allows participants to play casual games online while donating money to cure leukemia, lymphoma and myeloma.



The site works by allowing players to purchase online tokens - $1 per token and a minimum of $10 - to play the games, such as solitaire and miniature golf. Each token purchased will help fund blood cancer research, provide critical information and support to patients and their families and help LLS advocate for issues impacting patients. Players have a choice of five games, with more to come. Tokens can be given to friends and family.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap